-DOCSTART- -X- O
The -X- _ O
humanization -X- _ O
of -X- _ O
animal -X- _ O
model -X- _ O
immune -X- _ O
systems -X- _ O
by -X- _ O
genetic -X- _ O
engineering -X- _ O
has -X- _ O
shown -X- _ O
great -X- _ O
promise -X- _ O
for -X- _ O
antibody -X- _ O
discovery -X- _ O
, -X- _ O
tolerance -X- _ O
studies -X- _ O
and -X- _ O
for -X- _ O
the -X- _ O
evaluation -X- _ O
of -X- _ O
vaccines. -X- _ O
Assessment -X- _ O
of -X- _ O
the -X- _ O
baseline -X- _ O
antibody -X- _ O
repertoires -X- _ O
of -X- _ O
unimmunized -X- _ O
model -X- _ O
animals -X- _ O
will -X- _ O
be -X- _ O
useful -X- _ O
as -X- _ O
a -X- _ O
benchmark -X- _ O
for -X- _ O
future -X- _ O
immunization -X- _ O
experiments. -X- _ O
We -X- _ O
characterized -X- _ O
the -X- _ O
heavy -X- _ O
chain -X- _ O
and -X- _ O
kappa -X- _ O
light -X- _ O
chain -X- _ O
antibody -X- _ O
repertoires -X- _ O
of -X- _ O
a -X- _ O
model -X- _ O
animal -X- _ O
, -X- _ O
the -X- _ O
OmniRat -X- _ B-Patient
, -X- _ O
by -X- _ O
high -X- _ O
throughput -X- _ O
antibody -X- _ O
sequencing -X- _ O
and -X- _ O
made -X- _ O
use -X- _ O
of -X- _ O
two -X- _ O
novel -X- _ O
datasets -X- _ O
for -X- _ O
comparison -X- _ O
to -X- _ O
human -X- _ O
repertoires. -X- _ O
Intra-animal -X- _ O
and -X- _ O
inter- -X- _ O
animal -X- _ O
repertoire -X- _ O
comparisons -X- _ O
reveal -X- _ O
a -X- _ O
high -X- _ O
level -X- _ O
of -X- _ O
conservation -X- _ O
in -X- _ O
antibody -X- _ O
diversity -X- _ O
between -X- _ O
the -X- _ O
lymph -X- _ O
node -X- _ O
and -X- _ O
spleen -X- _ O
and -X- _ O
between -X- _ O
members -X- _ O
of -X- _ O
the -X- _ O
species. -X- _ O
Multiple -X- _ B-Outcome
differences -X- _ I-Outcome
were -X- _ I-Outcome
found -X- _ I-Outcome
in -X- _ I-Outcome
both -X- _ I-Outcome
the -X- _ I-Outcome
heavy -X- _ I-Outcome
and -X- _ I-Outcome
kappa -X- _ I-Outcome
chain -X- _ I-Outcome
repertoires -X- _ I-Outcome
between -X- _ I-Outcome
OmniRats -X- _ I-Outcome
and -X- _ I-Outcome
humans -X- _ I-Outcome
including -X- _ I-Outcome
gene -X- _ I-Outcome
segment -X- _ I-Outcome
usage -X- _ I-Outcome
, -X- _ I-Outcome
CDR3 -X- _ I-Outcome
length -X- _ I-Outcome
distributions -X- _ I-Outcome
, -X- _ I-Outcome
class -X- _ I-Outcome
switch -X- _ I-Outcome
recombination -X- _ I-Outcome
, -X- _ I-Outcome
somatic -X- _ I-Outcome
hypermutation -X- _ I-Outcome
levels -X- _ I-Outcome
and -X- _ I-Outcome
in -X- _ I-Outcome
features -X- _ I-Outcome
of -X- _ I-Outcome
V -X- _ I-Outcome
( -X- _ I-Outcome
D -X- _ I-Outcome
) -X- _ I-Outcome
J -X- _ I-Outcome
recombination. -X- _ I-Outcome
The -X- _ O
Inference -X- _ O
and -X- _ O
Generation -X- _ O
of -X- _ O
Repertoires -X- _ O
( -X- _ O
IGoR -X- _ O
) -X- _ O
software -X- _ O
tool -X- _ O
was -X- _ O
used -X- _ O
to -X- _ O
model -X- _ O
recombination -X- _ O
in -X- _ O
VH -X- _ O
regions -X- _ O
which -X- _ O
allowed -X- _ O
for -X- _ O
the -X- _ O
quantification -X- _ O
of -X- _ O
some -X- _ O
of -X- _ O
these -X- _ O
differences. -X- _ O
Diversity -X- _ B-Outcome
estimates -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
OmniRat -X- _ I-Outcome
heavy -X- _ I-Outcome
chain -X- _ I-Outcome
repertoires -X- _ I-Outcome
almost -X- _ I-Outcome
reached -X- _ I-Outcome
that -X- _ I-Outcome
of -X- _ I-Outcome
humans -X- _ I-Outcome
, -X- _ I-Outcome
around -X- _ I-Outcome
two -X- _ I-Outcome
orders -X- _ I-Outcome
of -X- _ I-Outcome
magnitude -X- _ I-Outcome
less. -X- _ I-Outcome
Despite -X- _ O
variation -X- _ O
between -X- _ O
the -X- _ O
species -X- _ O
repertoires -X- _ O
, -X- _ O
a -X- _ B-Outcome
high -X- _ I-Outcome
frequency -X- _ I-Outcome
of -X- _ I-Outcome
OmniRat -X- _ I-Outcome
clonotypes -X- _ I-Outcome
were -X- _ I-Outcome
also -X- _ I-Outcome
found -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
human -X- _ I-Outcome
repertoire. -X- _ I-Outcome
These -X- _ O
data -X- _ O
give -X- _ O
insights -X- _ O
into -X- _ O
the -X- _ O
development -X- _ O
and -X- _ O
selection -X- _ O
of -X- _ O
humanized -X- _ O
animal -X- _ O
antibodies -X- _ O
and -X- _ O
provide -X- _ O
actionable -X- _ O
information -X- _ O
for -X- _ O
use -X- _ O
in -X- _ O
vaccine -X- _ O
studies -X- _ O
. -X- _ O

